查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2025032

奈米醫學市場規模、佔有率、趨勢和預測：按奈米分子類型、產品類型、應用和地區分類，2026-2034年

Nanomedicine Market Size, Share, Trends and Forecast by Nanomolecule Type, Product, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球奈米醫學市場規模為3,260億美元。展望未來，IMARC Group預測，該市場將以10.43%的複合年成長率從2026年成長至2034年，到2034年達到8,175億美元。北美目前在該市場主導，2025年市佔率高達49.9%。奈米醫學市場成長的主要促進因素包括：對標靶藥物遞送的需求不斷成長、奈米技術的進步、慢性病患病率的上升、在診斷和治療領域應用範圍的擴大，以及為開發更有效、個性化和微創的醫療治療方法而加大研發投入。

奈米醫學市場的主要驅動力是奈米技術的進步及其在醫療保健領域的應用。標靶藥物遞送系統的開發提高了醫療療效，減輕了副作用，尤其是在癌症、心臟病和腦部疾病方面。隨著慢性病患者人數的增加，尋求更有效的治療方法變得日益重要。此外，奈米技術在診斷、再生醫學和影像領域的日益廣泛應用，正在改善疾病的早期檢測和個人化治療。公共和私營部門在奈米醫學研發領域的積極活動，為該市場的經濟成長提供了支持。在廣泛的監管支援和新藥研發的推動下，奈米醫學正成為未來全球醫療解決方案的關鍵組成部分。

美國奈米醫藥市場的成長主要得益於奈米技術的進步。這些進步促進了標靶藥物遞送系統的發展，從而提高了治療效果並減少了副作用。心血管疾病和癌症等慢性疾病的日益普遍，進一步增加了對創新治療方案的需求。根據美國國立衛生研究院 (NIH) 預測，到 2025 年，美國將新增約 2,041,910 例癌症病例，並有 618,120 例死亡病例。來自公共和私營部門的大量投資支持了廣泛的研發活動，推動了該領域的創新。美國食品藥物管理局(FDA) 提供了有利的法規環境，促進了奈米醫藥產品的核准和商業化。此外，人們對個人化醫療和疾病早期檢測的日益關注，正在拓展奈米技術在診斷和治療領域的應用範圍，進一步推動市場成長。

奈米醫療市場趨勢

奈米科技的進步

奈米技術的持續創新是奈米醫學市場擴張的主要驅動力。研究人員開發了奈米級材料和裝置，實現了精準藥物傳輸、標靶治療和先進的診斷成像技術。這些突破性進展透過最大限度地減少副作用和提高治療精度，改善了治療效果。奈米顆粒、脂質體、樹狀聚合物和奈米機器人正被開發用於從癌症治療到組織修復等廣泛的應用領域。診斷工具的小型化也使即時監測和疾病早期檢測更加有效。隨著奈米技術的不斷發展，複雜疾病的管理領域正在湧現新的可能性，為醫療專業人員提供更精密、更微創的工具。奈米醫學市場預測表明，這些創新是推動整個醫療保健產業對奈米醫學日益成長的接受度和投資的關鍵因素。例如，2025年5月，專注於奈米醫學的受託研究機構Nanoworx BV向學術界和產業界合作夥伴提供了其廣泛的服務組合。 Nanoworx 公司成立於荷蘭埃因霍溫，利用最先進的設備和豐富的經驗來推動基於奈米顆粒的解決方案的設計、開發和規模化。

加大研發投入

公共和私營部門的大量投資正在推動奈米醫學的進步。各國政府、研究機構和製藥公司都在大力投資開發基於奈米技術的新治療方法、診斷方法和藥物傳輸系統。這些投資正在加速創新，並推動奈米醫學從實驗室走向臨床應用。大學、生物技術公司和醫療保健機構之間的合作正在促進跨學科研究，從而帶來新的發現和產品的快速商業化。此外，創業投資對奈米技術新創企業的支持正在幫助早期創新成果走向市場。這種強勁的資金籌措環境使得人們能夠不斷探索基於奈米技術的解決方案來滿足尚未滿足的需求，從而使奈米醫學成為全球醫療保健產業成長的關鍵領域和技術領導者。例如，2024年4月，CBC公司和芬蘭奈米製藥有限公司（簡稱「Nanoform」）宣佈建立策略夥伴關係。此次合作將使CBC能夠利用其對日本製藥業的深入了解，並探索Nanoform尖端奈米醫學工程技術的商業機會。奈米級藥物，無論是新型治療方法還是現有產品的重新配方，都已證明能夠透過減少劑量和服用片劑的數量來提高患者的接受度，並解決藥物生物利用度問題，而藥物生物利用度是製藥公司關注的問題。

有利的監管支持和臨床進展

支持性的法律規範和持續的臨床進展為奈米藥物市場創造了光明的前景。美國FDA和EMA等監管機構已建立評估和核准奈米技術產品的流程，增強了研發者和消費者的信心。簡化的審查流程、指導文件和監管澄清正在加速產品開發和市場准入。同時，越來越多奈米藥物治療方法的臨床試驗取得成功，證明了其安全性和有效性，這在公共衛生領域和投資者中引起了廣泛關注。監管機構也支持上市後監測和品管標準，以持續確保病人安全。這些監管支持與臨床證據相結合，正在加速奈米藥物產品的應用，增強市場信心，並促進其更廣泛地融入醫療保健系統。例如，2024年9月，芝加哥大學醫學中心綜合癌症中心的研究人員開發了一種奈米藥物，該藥物能夠有效破壞小鼠體內的癌細胞，並提高化療藥物在腫瘤組織中的滲透性和蓄積性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球奈米醫學市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依奈米分子類型分類

  • 奈米顆粒
    • 主要類型
      • 金屬和金屬氧化物奈米顆粒
      • 脂質體
      • 聚合物和聚合物-藥物複合物
      • 水凝膠奈米顆粒
      • 樹狀聚合物
      • 無機奈米粒子
  • 奈米殼
  • 奈米管
  • 奈米裝置

第7章 市場區隔：依產品分類

  • 治療
  • 再生醫學
  • 體外診斷試劑
  • 體內診斷
  • 疫苗

第8章 市場區隔：依應用領域分類

  • 臨床腫瘤學
  • 感染疾病
  • 臨床心臟病學
  • 整形外科
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Arrowhead Pharmaceuticals Inc.
    • General Electric Company
    • Luminex Corporation
    • Merck & Co. Inc.
    • Nanobiotix
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Starpharma Holdings Limited
Product Code: SR112026A4052

The global nanomedicine market size was valued at USD 326.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 817.5 Billion by 2034, exhibiting a CAGR of 10.43% during 2026-2034. North America currently dominates the market, holding a significant market share of 49.9% in 2025. The rising demand for targeted drug delivery, advancements in nanotechnology, increased prevalence of chronic diseases, expanding applications in diagnostics and therapeutics, and growing investments in research and development to create more effective, personalized, and minimally invasive medical treatments are some of the major factors fueling the nanomedicine market share.

The market for nanomedicine is primarily fueled by advancements in nanotechnology and its growing integration into healthcare applications. The development of targeted drug delivery systems has increased the benefits of medical treatments and decreased the side effects mainly seen in cancers and heart and brain conditions. With the growing number of people having chronic diseases, the search for better treatments becomes more important. In addition, the use of nanotechnology for diagnostics, regenerative medicine and imaging is increasing, improving both early finding of diseases and tailored care. The economic growth of the market is supported by greater activity from both public and private sectors in nanomedicine research and development (R&D). Because of general support from regulators and new drug studies, nanomedicine is becoming a crucial aspect of future medical solutions globally.

The nanomedicine market growth in the United States is propelled by advancements in nanotechnology, which have facilitated the development of targeted drug delivery systems and enhanced treatment efficacy and reducing side effects. The rising prevalence of chronic diseases, like cardiovascular conditions and cancer, has amplified the demand for innovative therapeutic solutions. According to the NIH, in 2025, approximately 2,041,910 new cancer cases are likely to be identified in the United States, with 618,120 individuals succumbing to the illness. Substantial investments from private and public sectors support extensive research and development (R&D) activities, fostering innovation in the field. The U.S. Food and Drug Administration (FDA) provides a favorable regulatory environment that facilitates the approval and commercialization of nanomedicine products. Additionally, the growing emphasis on personalized medicine and early disease detection has expanded the applications of nanotechnology in diagnostics and therapeutics, further driving market growth.

NANOMEDICINE MARKET TRENDS

Advancements in Nanotechnology

Ongoing innovations in nanotechnology are a primary force behind the expansion of the nanomedicine market. Researchers have developed nanoscale materials and devices that enable precise drug delivery, targeted therapy, and enhanced imaging techniques. These breakthroughs improve therapeutic outcomes by minimizing side effects and increasing treatment accuracy. Nanoparticles, liposomes, dendrimers, and nanorobots are being engineered for applications ranging from cancer treatment to tissue repair. The miniaturization of diagnostic tools has also made real-time monitoring and early disease detection more effective. As nanotechnology continues to evolve, it opens new possibilities for complex disease management, providing healthcare professionals with more refined, less invasive tools. According to the nanomedicine market forecast, these innovations are central to the increasing adoption and investment in nanomedicine across the healthcare industry. For instance, in May 2025, Nanoworx B.V., a nanomedicine-focused contract research organization, provided its extensive service portfolio for partners in academia and business. Nanoworx, a company established in Eindhoven, the Netherlands, advances the design, development, and scalability of nanoparticle-based solutions by utilizing cutting-edge machinery and extensive experience.

Growing Investments in Research and Development

Significant investments from both public and private sectors are fueling advancements in nanomedicine. Governments, research institutions, and pharmaceutical companies are allocating substantial funding to develop novel nanotechnology-based therapies, diagnostics, and drug delivery systems. These investments accelerate innovation and the transition of nanomedicine from the lab to clinical applications. Collaborations among universities, biotech firms, and healthcare providers are promoting interdisciplinary research, leading to new discoveries and faster commercialization of products. Moreover, venture capital support for nanotech startups is helping to bring early-stage innovations to market. This robust funding environment enables continued exploration of nano-based solutions for unmet medical needs, positioning nanomedicine as a key area of growth and technological leadership within the global healthcare landscape. For instance, in April 2024, CBC Co., Ltd. and Nanoform Finland Plc ("Nanoform") announced a strategic cooperation in which CBC would use its vast knowledge of the Japanese pharmaceutical sector to find opportunities for Nanoform's state-of-the-art nanomedicine engineering technology. It has been demonstrated that nano-formed medications, whether they are novel treatments or reformulated versions of existing goods, can increase patient acceptance by reducing dose size and pill load and resolving innovators' concerns about drug bioavailability.

Favorable Regulatory Support and Clinical Advancements

Supportive regulatory frameworks and ongoing clinical advancements are creating a positive nanomedicine market outlook. Regulatory bodies such as the U.S. FDA and EMA have created pathways to evaluate and approve nanotechnology-based products, fostering confidence among developers and consumers. Streamlined review processes, guidance documents, and regulatory clarity help accelerate product development and market entry. In parallel, increasing numbers of successful clinical trials for nanomedicine-based therapies validate their safety and effectiveness, building momentum in both public health and investor interest. Regulatory agencies also support post-market surveillance and quality control standards, ensuring continued patient safety. This combination of regulatory support and clinical validation enables wider adoption of nanomedicine products, reinforcing trust and facilitating broader integration into healthcare systems. For instance, in September 2024, researchers at the University of Chicago Medicine Comprehensive Cancer Center shaped a nanomedicine that efficiently destroys cancer cells in mice and improves the penetration and buildup of chemotherapy medications in tumor tissues.

NANOMEDICINE INDUSTRY SEGMENTATION:

Analysis by Nanomolecule Type:

  • Nanoparticles
    • Metal and Metal Oxide Nanoparticles
    • Liposomes
    • Polymers and Polymer Drug Conjugates
    • Hydrogel Nanoparticles
    • Dendrimers
    • Inorganic Nanoparticles
  • Nanoshells
  • Nanotubes
  • Nanodevices

Nanoparticles stand as the largest nanomolecule type in 2025, holding 76.7% of the market due to their exceptional versatility, precision, and effectiveness in delivering therapeutic agents. Their small size allows them to penetrate biological barriers and accumulate in target tissues, particularly tumors, through enhanced permeability and retention (EPR) effects. This enables targeted drug delivery, reducing toxicity to healthy cells and improving treatment outcomes. Additionally, nanoparticles can be engineered with surface modifications to enhance the solubility, stability, and bioavailability of drugs. Their applications span a wide range of medical fields, including oncology, cardiology, infectious diseases, and neurology. With growing investments in research, continuous innovation, and increasing adoption in clinical trials, nanoparticles remain the preferred platform for developing next-generation nanomedicines across diagnostics, therapeutics, and regenerative medicine.

Analysis by Product:

  • Therapeutics
  • Regenerative Medicine
  • In-Vitro Diagnostics
  • In-Vivo Diagnostics
  • Vaccines

Therapeutics leads the market with 34.7% of market share in 2025 due to their transformative role in enhancing treatment efficacy, reducing side effects, and enabling targeted drug delivery. Nanotherapeutics offer precise delivery of active pharmaceutical ingredients to specific cells or tissues, which is especially valuable in treating complex diseases such as cardiovascular disorders, cancer, and neurological conditions. This precision reduces damage to healthy cells and improves patient outcomes. Additionally, nanomedicine enables controlled and sustained drug release, increasing bioavailability and patient compliance. As chronic diseases become more prevalent globally, the demand for advanced therapeutic solutions continues to rise. Coupled with strong investment in research and development (R&D) and numerous ongoing clinical trials, the therapeutic segment remains the most commercially mature and widely adopted application within the nanomedicine market.

Analysis by Application :

  • Clinical Oncology
  • Infectious Diseases
  • Clinical Cardiology
  • Orthopedics
  • Others

Clinical oncology leads the market with 32.5% of market share in 2025 due to the high demand for more effective and targeted cancer treatments. Nanomedicine enables the delivery of chemotherapeutic agents directly to tumor cells while minimizing exposure to healthy tissues, significantly reducing side effects and improving treatment outcomes. This precision is crucial in oncology, where conventional therapies often cause severe systemic toxicity. Additionally, nanocarriers improve drug solubility and bioavailability, and can bypass drug resistance mechanisms in tumors. The increasing global cancer burden has driven extensive research, development, and clinical adoption of nanotechnology-based therapies. With numerous nanomedicine oncology products already approved or in advanced clinical trials, this application continues to lead the market, supported by strong investment and regulatory interest in cancer innovation.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 49.9%. The nanomedicine market demand in North America is influenced by a combination of advanced healthcare infrastructure, strong research capabilities, and significant investment in nanotechnology. The region benefits from a high prevalence of chronic diseases, like cardiovascular disorders and cancer, which increases demand for targeted and effective treatment options. Robust support from government agencies, including funding for nanomedicine research through institutions like the NIH, accelerates innovation and clinical translation. Additionally, the presence of leading pharmaceutical and biotechnology companies fosters the development and commercialization of nanomedicine products. Regulatory agencies like the FDA provide structured pathways for approval, encouraging product adoption. With growing awareness of precision medicine and early diagnosis, North America remains a global leader in nanomedicine research, development, and market share growth.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NANOMEDICINE MARKET ANALYSIS

In 2025, the United States accounted for 92.60% of the nanomedicine market in North America. The United States nanomedicine market is mainly fueled by the increasing prevalence of chronic conditions, such as cancer and neurological disorders. According to the NCI, an estimated 2,041,910 new cancer cases and 618,120 cancer deaths are expected in the U.S. in 2025. The cancer incidence rate is 445.8 per 100,000 people annually (2018-2022), while the mortality rate is 145.4 per 100,000 people annually (2019-2023). By this, growing federal and private investment in nanotechnology R&D is accelerating innovation and commercialization in the sector. Similarly, the increasing presence of leading research institutions and academic partnerships is enabling efficient technology transfer and product development. Furthermore, continual regulatory advancements, including the FDA's adaptive pathways for nanomedicines, are facilitating smoother clinical translation and impelling the market. Additionally, expanding applications in regenerative medicine, including stem cell nanocarriers and scaffold integration, are widening the market scope. The rising demand for precision therapies, encouraging the development of nanoparticle-based diagnostics and treatments, is strengthening the market demand. Likewise, strong industry participation in targeted delivery platforms is enhancing therapeutic efficacy and market appeal. Moreover, strategic collaborations and licensing deals are further accelerating innovation and market penetration.

EUROPE NANOMEDICINE MARKET ANALYSIS

The market in Europe is experiencing growth due to rising public healthcare investment and strategic funding initiatives under Horizon Europe. According to Eurostat, in 2022, 51.3% of existing healthcare spending in the EU was funded through mandatory schemes and savings accounts, 30.0% by governmental programs, while the final 18.7% was provided by other funding sources. In line with this, expanding adoption of nanosensors in early disease detection technologies, supporting diagnostic accuracy and speed, is propelling the market growth. The region's ongoing shift toward personalized healthcare is encouraging the uptake of targeted nanotherapies, especially in oncology and rare diseases. Furthermore, the well-regulated clinical trial environment across Europe is enabling efficient testing and approval of novel nanomedicine products. Furthermore, continual technological advances in nanoparticle design are allowing more controlled drug release, improving patient outcomes, and treatment adherence. Similarly, increasing collaboration between universities, biotech startups, and pharma firms is accelerating market expansion. The growing focus on non-invasive delivery platforms such as intranasal and transdermal nanoformulations is broadening market reach. Moreover, strong emphasis on research-driven innovation, solidifying Europe's leadership in nanomedicine development, is creating lucrative market opportunities.

ASIA PACIFIC NANOMEDICINE MARKET ANALYSIS

The Asia Pacific nanomedicine market is majorly driven by rising healthcare expenditure and the increasing burden of chronic diseases across rapidly developing economies. In addition to this, government-supported nanotechnology programs in China, Japan, and South Korea are strengthening regional research infrastructure and translational capabilities, which is impelling the market. Similarly, the growing role of contract research and manufacturing organizations, enabling efficient and cost-effective development of nanomedicine solutions, is fostering market expansion. Furthermore, the rapid integration of artificial intelligence with nanotechnology for targeted drug delivery is enhancing treatment accuracy and personalization, thereby stimulating market appeal. Apart from this, the rise in medical tourism across countries such as India, Thailand, and Malaysia, generating demand for advanced, minimally invasive therapies, is providing an impetus to the market. According to data shared in the Parliament, foreign medical visitors to India reached nearly 6.6 lakh in 2023, reflecting steady post-pandemic growth.

LATIN AMERICA NANOMEDICINE MARKET ANALYSIS

In Latin America, the market is advancing due to rising government-backed initiatives focused on biotechnology and nanoscience through national development agendas. Similarly, the growth of public-private research collaborations, enhancing regional capacity for innovation and infrastructure development, is propelling the market growth. Furthermore, the increasing burden of infectious diseases is prompting healthcare systems to adopt nano-enabled diagnostics and drug delivery platforms for greater therapeutic precision. Moreover, the expansion of clinical trial networks in countries like Brazil and Argentina, supported by regulatory reforms and competitive operating costs, is attracting global investments in nanotechnology-driven healthcare solutions. According to the Regulatory Affairs Professionals Society (RAPS), as of April 2024, around 10,000 clinical studies were recorded in Brazil, positioning it as the frontrunner in clinical trials within Latin America, with Mexico trailing at approximately 5,000 and Argentina at 4,000.

MIDDLE EAST AND AFRICA NANOMEDICINE MARKET ANALYSIS

The market in the Middle East and Africa is advancing with increased public investment in healthcare innovation, particularly through national transformation plans in countries like Saudi Arabia and the UAE. Furthermore, the rising burden of non-communicable diseases, such as cancer and diabetes, is encouraging the adoption of nanomedicine for targeted treatment and precision diagnostics. As per NCBI, the GCC countries saw an expected 42,475 new cases of cancer and 19,895 deaths in 2020; the age-standardized incidence and mortality rates were 96.5 and 52.3 per 100,000, respectively. Additionally, growing collaboration with global research institutions is enhancing regional access to cutting-edge nanotechnology and accelerating product development. Besides this, expanding interest in personalized healthcare solutions across urban medical centers supporting the integration of nanotherapeutics into mainstream treatment pathways is impacting market dynamics.

COMPETITIVE LANDSCAPE:

The nanomedicine market is highly competitive, characterized by a mix of established pharmaceutical companies, innovative biotech startups, and academic research institutions. Key players such as Pfizer, Johnson & Johnson, Abbott Laboratories, and Merck & Co. are actively investing in nanotechnology to enhance drug delivery systems and develop advanced therapies. Emerging companies like Nanoform, Nanobiotix, and Selecta Biosciences are gaining traction with specialized platforms for targeted treatment. Collaborations, licensing agreements, and strategic partnerships are common as firms seek to expand their technological capabilities and market reach. Continuous innovation, strong R&D pipelines, and a focus on oncology and chronic disease treatment are central to competitive positioning. Regulatory approvals and clinical trial progress play critical roles in shaping market leadership and driving commercial success.

The report provides a comprehensive analysis of the competitive landscape in the nanomedicine market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Arrowhead Pharmaceuticals Inc.
  • General Electric Company
  • Luminex Corporation
  • Merck & Co. Inc.
  • Nanobiotix
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Starpharma Holdings Limited

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the nanomedicine market?

2. What is the future outlook of nanomedicine market?

3. What are the key factors driving the nanomedicine market?

4. Which region accounts for the largest nanomedicine market share?

5. Which are the leading companies in the global nanomedicine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Nanomedicine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Nanomolecule Type

  • 6.1 Nanoparticles
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Metal and Metal Oxide Nanoparticles
      • 6.1.2.2 Liposomes
      • 6.1.2.3 Polymers and Polymer Drug Conjugates
      • 6.1.2.4 Hydrogel Nanoparticles
      • 6.1.2.5 Dendrimers
      • 6.1.2.6 Inorganic Nanoparticles
    • 6.1.3 Market Forecast
  • 6.2 Nanoshells
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Nanotubes
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Nanodevices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Therapeutics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Regenerative Medicine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 In-Vitro Diagnostics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 In-Vivo Diagnostics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Vaccines
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Clinical Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinical Cardiology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Orthopedics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arrowhead Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 General Electric Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Luminex Corporation
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Nanobiotix
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi SA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Starpharma Holdings Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials

List of Figures

  • Figure 1: Global: Nanomedicine Market: Major Drivers and Challenges
  • Figure 2: Global: Nanomedicine Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Nanomedicine Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Nanomedicine Market: Breakup by Nanomolecule Type (in %), 2025
  • Figure 5: Global: Nanomedicine Market: Breakup by Product (in %), 2025
  • Figure 6: Global: Nanomedicine Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Nanomedicine Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Nanomedicine (Nanoparticles) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Nanomedicine (Nanoparticles) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Nanomedicine (Nanoshells) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Nanomedicine (Nanoshells) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Nanomedicine (Nanotubes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Nanomedicine (Nanotubes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Nanomedicine (Nanodevices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Nanomedicine (Nanodevices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Nanomedicine (Therapeutics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Nanomedicine (Therapeutics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Nanomedicine (Regenerative Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Nanomedicine (Regenerative Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Nanomedicine (In-Vitro Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Nanomedicine (In-Vitro Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Nanomedicine (In-Vivo Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Nanomedicine (In-Vivo Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Nanomedicine (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Nanomedicine (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Nanomedicine (Clinical Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Nanomedicine (Clinical Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Nanomedicine (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Nanomedicine (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Nanomedicine (Clinical Cardiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Nanomedicine (Clinical Cardiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Nanomedicine (Orthopedics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Nanomedicine (Orthopedics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Nanomedicine (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Nanomedicine (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: North America: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: North America: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: United States: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: United States: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Canada: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Canada: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Asia-Pacific: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Asia-Pacific: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: China: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: China: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Japan: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Japan: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: India: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: India: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: South Korea: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: South Korea: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Australia: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Australia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Indonesia: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Indonesia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Others: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Europe: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Europe: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Germany: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Germany: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: France: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: France: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: United Kingdom: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: United Kingdom: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Italy: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Italy: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Spain: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Spain: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Russia: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Russia: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Latin America: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Latin America: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Brazil: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Brazil: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Mexico: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Mexico: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Middle East and Africa: Nanomedicine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Middle East and Africa: Nanomedicine Market: Breakup by Country (in %), 2025
  • Figure 84: Middle East and Africa: Nanomedicine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Global: Nanomedicine Industry: SWOT Analysis
  • Figure 86: Global: Nanomedicine Industry: Value Chain Analysis
  • Figure 87: Global: Nanomedicine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Nanomedicine Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Nanomedicine Market Forecast: Breakup by Nanomolecule Type (in Million USD), 2026-2034
  • Table 3: Global: Nanomedicine Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 4: Global: Nanomedicine Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Nanomedicine Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Nanomedicine Market: Competitive Structure
  • Table 7: Global: Nanomedicine Market: Key Players